Amarin Corp Plcuk (AMRN) Accounts Payables (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Accounts Payables of $48.2 million for Q1 2026, up 5.46% YoY from $45.7 million in Q1 2025, and up 6.17% sequentially from $45.4 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Accounts Payables (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Accounts Payables across 17 years of filings, most recently posting $48.2 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 5.46% year-over-year to $48.2 million; the TTM figure through Mar 2026 stood at $48.2 million (up 5.46% YoY), while the FY2025 annual figure was $45.4 million, up 12.36% from the prior year.
- Accounts Payables climbed to $48.2 million in Q1 2026, from $45.4 million in the prior quarter.
- Over the last five years, Accounts Payables for AMRN reached as high as $116.3 million in Q2 2022 and fell as low as $36.7 million in Q3 2025.
- The 5-year median for Accounts Payables is $53.4 million (2023), against an average of $59.3 million.
- Annual changes were most pronounced in 2022 — Accounts Payables climbed 28.64% — and 2023, when it plunged 53.31%.
- A 5-year view of Accounts Payables shows it stood at $64.6 million in 2022, then fell by 18.33% to $52.8 million in 2023, then declined by 23.49% to $40.4 million in 2024, then grew by 12.36% to $45.4 million in 2025, then climbed by 6.17% to $48.2 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $48.2 million, $45.4 million, and $36.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.03 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 10.46 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 33.77 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -22.51 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 3.86 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 48.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.15 Mn |
| Dec 31, 2025 | 45.36 Mn |
| Sep 30, 2025 | 36.71 Mn |
| Jun 30, 2025 | 44.71 Mn |
| Mar 31, 2025 | 45.66 Mn |
| Dec 31, 2024 | 40.37 Mn |
| Sep 30, 2024 | 40.51 Mn |
| Jun 30, 2024 | 54.38 Mn |
| Mar 31, 2024 | 67.60 Mn |
| Dec 31, 2023 | 52.76 Mn |
| Sep 30, 2023 | 53.36 Mn |
| Jun 30, 2023 | 54.31 Mn |
| Mar 31, 2023 | 58.78 Mn |
| Dec 31, 2022 | 64.60 Mn |
| Sep 30, 2022 | 93.16 Mn |
| Jun 30, 2022 | 116.31 Mn |
| Mar 31, 2022 | 90.75 Mn |
| Dec 31, 2021 | 114.92 Mn |
| Sep 30, 2021 | 72.42 Mn |
| Jun 30, 2021 | 141.25 Mn |